Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging
A phase 2 trial of HER2 PET in Breast cancer, run by Peking University Cancer Hospital & Institute, not yet recruiting.
Overview
Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging is a phase 2 interventional study registered as NCT07527806 by Peking University Cancer Hospital & Institute, with 156 participants planned, started 2026-05-01 and due to reach its primary completion in 2029-05-01. Interventions recorded: Trastuzumab (Herceptin), Pertuzumab, Combination product: Trastuzumab + Pertuzumab, Docetaxel or Nab-paclitaxel, carboplatin, CDK4/6 inhibitor, Aromatase Inhibitor (AI), ADC. Conditions recorded: Breast Cancer.
Linked to the technology HER2 PET because the registry's title names it ("her2 pet") and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- Trial[68Ga]Ga-ABY-025 PET for Quantification of HER2-status in Solid Tumors
Shares HER2 PET, Breast cancer (all types) and the tag pipeline.
- TrialDocetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
Shares Pertuzumab, Breast cancer (all types), Trastuzumab, Carboplatin and the tag pipeline.
- TrialMARGetuximab Or Trastuzumab (MARGOT)
Shares Pertuzumab, Breast cancer (all types), Trastuzumab and the tag pipeline.
- TrialA Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial
Shares Pertuzumab, Trastuzumab and the tag pipeline.
- TrialA Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor
Shares Pertuzumab, Trastuzumab and the tag pipeline.
- TrialSafety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors
Shares Pertuzumab, Trastuzumab and the tag pipeline.
- TrialMargetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
Shares Breast cancer (all types), Trastuzumab and the tag pipeline.
- TrialA Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer
Shares Breast cancer (all types), Carboplatin and the tag pipeline.